市公司 句研究/公司书 | | | | 市场数据: 2026年03月03日 | | --- | | 收盘价（元） 185.75 | | 一年内最高/最低（元） 589.98/185.10 | | 市净率 11.6 | | 股息率%（分红/股价） 1.62 | | 流通 A 股市值 (百万元) 10,199 | | 上证指数/深证成指 | | 注："股息率"以最近一年已公布分红计算 | | 基础数据: | 2025年09月30日 | | --- | --- | | 每股净资产 (元) | 16.01 | | 资产负债率% | 25.26 | | 总股本/流通 A 股 (百万) | 115/55 | | 流通 B 股/H 股 (百万) | -/- | 年内股价与大盘对比定势： an and the seat the same of the same of 相关研究 证券分析师 刘靖 A0230512070005 liujinq@swsresearch.com 王雨晴 A0230522010003 wangyq@swsresearch.com 联系人 王雨晴 A0230522010003 wangyq@swsres ...

上 市 公 司 公 司 研 究 / 公 司 点 评 证 券 研 究 报 告 | 报告原因：有业绩公布需要点评 | | --- | | 买入（维持） | | 市场数据： | 2026 年 03 月 03 日 | | --- | --- | | 收盘价（元） | 185.75 | | 一年内最高/最低（元） | 589.98/185.10 | | 市净率 | 11.6 | | 股息率%（分红/股价） | 1.62 | | 流通 A 股市值（百万元） | 10,199 | | 上证指数/深证成指 | 4,122.68/14,022.39 | | 注："股息率"以最近一年已公布分红计算 | | | 基础数据: | 2025 年 09 月 30 日 | | --- | --- | | 每股净资产（元） | 16.01 | | 资产负债率% | 25.26 | | 总股本/流通 A 股（百万） | 115/55 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： -50% 0% 50% 100% 150% 200% 03-03 04-03 05-03 06-03 07-03 08-03 09 ...

Summary of China Cosmetics Conference Call Industry Overview - The focus is on the **anti-aging beauty market** in China, which includes traditional anti-aging skincare, medical aesthetics (MA), and dermocosmetics. - The market is expected to grow at a **high single-digit CAGR** over the period from 2025 to 2030, with medical aesthetics and dermocosmetics leading at **9%** and anti-aging skincare at **6%** [1][22]. Key Insights Market Penetration and Demographics - The current penetration of the MA market in China is low, estimated at **5%** for the core consumer group aged **20-60**, compared to **10%-20%** in developed markets. It is expected to rise to **8%** by **2030E**, supporting a **10% CAGR** for MA users [2][22]. - Anti-aging skincare is seeing earlier adoption among younger consumers, with approximately **40%** of this demographic engaging with the category, which is expected to drive further expansion [2][22]. Pricing Dynamics - More resilient pricing is anticipated from **2026E** due to stricter regulations and healthier competition, with limited supply tailwinds favoring recombinant collagen. The MA market has experienced sharp price reductions due to intense competition, but future pricing is expected to stabilize [3][22]. - Factors contributing to this stabilization include more accessible pricing in China and a narrower price gap with Korea following recent policy changes [3][22]. Company Recommendations - **Forest Cabin** is initiated with a **Buy** rating, expected to benefit from growth in oil-based anti-aging skincare, with a projected **48% sales CAGR** from **2022-2025E** and **32%/29% sales/NP CAGR** from **2025-2028E** [4][22]. - **Giant Biogene** is also rated **Buy** due to its integrated value chain from MA to dermocosmetics, enhancing R&D and brand recognition [4][22]. - **Proya** is viewed as a domestic leader in the anti-aging sector but is rated **Neutral** pending further evidence of the new management's execution track record [4][22]. Market Growth Projections - The overall anti-aging market in China is projected to grow from **RMB 214 billion** in **2024E** to **RMB 398 billion** by **2030E**, reflecting a **CAGR of 8%** [20][22]. - Medical aesthetics is expected to contribute significantly to this growth, with a **10.3% volume CAGR** over the same period, despite ongoing pricing pressures in certain categories [17][22]. Additional Insights - The report emphasizes the importance of companies with larger sales exposure to growth segments, stronger market positions, and better operational execution, including R&D capabilities [10][22]. - The anti-aging skincare segment is projected to see a shift towards functionalities beyond basic moisturizing, with penetration expected to increase from **25.6% to 29.0%** from **2025 to 2030E** [19][22]. Conclusion - The anti-aging beauty market in China presents significant growth opportunities driven by demographic shifts, evolving consumer perceptions, and technological advancements. Companies like Forest Cabin and Giant Biogene are well-positioned to capitalize on these trends, while pricing dynamics and market penetration will play crucial roles in shaping the competitive landscape.

Core Insights - The Chinese medical beauty market is experiencing a significant transformation in 2025, marked by a notable divergence in the performance of various brands within the regenerative filling materials sector, with "Zhenai Su Fei" leading with a 463% growth while "Yiyan Shi" saw a 56% decline [1][2] - The market is witnessing a "Matthew Effect," where leading brands are consolidating their positions, while smaller brands struggle to survive [1][10] Regenerative Filling Materials - Regenerative filling materials have become the "MVP" of the year, with a 93.40% increase in sales in 2025, continuing a three-year growth trend [2] - "Zhenai Su Fei" from Aimeike achieved the highest growth rate at 463%, while "Yiyan Shi" faced a significant decline of 56% [2][3] - The performance of "Yiyan Shi" is attributed to its early market entry, but its novelty has worn off, leading to decreased consumer interest [3] Market Dynamics - The market is increasingly competitive, with new brands and materials entering, but consumers tend to prefer established brands for their reliability [4] - The sales of the once-popular ultrasonic device have dropped significantly, with a 55.2% decline in 2025, as consumers are opting for newer products and are more budget-conscious [4][5] Equipment and Technology - The "Meila Meisu" ultrasonic knife has emerged as a leading anti-aging device, with a 147.22% increase in sales, appealing to users over 35 seeking non-invasive treatments [4][5] - The ultrasonic device is transitioning from a "market dividend period" to a "technical barrier period," indicating a shift in competitive dynamics [5][7] Hyaluronic Acid - Hyaluronic acid remains a top-selling product, with a 19.70% increase in sales in 2025, maintaining its status as a staple in the market [8] - Despite its growth, hyaluronic acid faces challenges such as market oversupply and price wars, which could weaken its position in the long term [8][9] Future Growth Areas - The market is shifting towards specialized treatments, with a focus on individual needs and the emergence of new segments like collagen reorganization and hair loss treatment, which are expected to see significant growth [10][11] - The collagen reorganization market is projected to grow at a compound annual growth rate of 41.4% from 2023 to 2027, indicating strong potential [10]

Group 1 - The core viewpoint of the article highlights that Giant Bio (02367) has seen a significant stock price increase, with a rise of over 8% during trading, currently at 34.4 HKD and a trading volume of 256 million HKD [1] - Giant Bio recently announced the approval of its "recombinant type I α1 collagen and sodium hyaluronate composite solution" as a Class III medical device, marking it as the world's first implant product aimed at improving cheek smoothness [1] - CICC expresses optimism regarding the product's approval, which is expected to further expand the company's aesthetic medicine product matrix and validate its leading technological research and development capabilities [1] Group 2 - The long-term outlook from CICC suggests that the company's research and development strength, brand recognition, and team cohesion remain solid [1] - As the cosmetics market recovers and the contribution from aesthetic medicine increases, CICC recommends paying attention to investment opportunities in the company [1]

"内卷"已然成为中国化妆品行业的普遍焦虑与日常现实。一方面，行业已步入个位数的慢增长 新常态——根据中国香料香精化妆品工业协会数据，2 0 2 5年全渠道交易额增速仅为2 . 8 3%。另 一方面，曾经汹涌的流量红利逐渐退潮，同质化竞争白热化，生存挑战急剧上升：行业数据显 示，2 0 1 6 - 2 0 2 0年间成立的国货美妆品牌，能存活超过5年的不足1 2%；即使在2 0 2 5年仍有超 过5 0个新品牌涌现，其中能迅速跃升为"亿级黑马"的也屈指可数。 在此背景下，福瑞达生物股份旗下第三大品牌珂谧（Ke yC）成绩尤其亮眼。 《FBe a u t y未来迹》获得的数据显示，珂谧品牌成立不到两年，便取得营收规模突破2亿元的 业绩，成为市场瞩目的新锐力量。尤其关键的是，它锚定以超2 0%年复合增长率扩张的轻医美 赛道、直面"重组胶原蛋白难以透皮"的核心科学瓶颈、系统性构建品牌专业信任体系，从而在 存量竞争中开辟增量空间。 在行业一片关于成本高企与增长乏力的讨论中，寻找结构性的新增长点，成为破局的关键。 在红海之下，却有一股强劲而持续的结构性增长潜流正在涌动。据嘉世咨询的研究数据显示， 中国轻医美市场规模从2 ...

Core Viewpoint - The "Top Ten Outstanding Figures in the Medical Aesthetics Industry for 2025" list was announced, highlighting key leaders in the sector, including Yan Jianya, Chairman of Juzi Biotechnology, who was recognized for his contributions and leadership [1][2]. Group 1: Industry Recognition - The list was compiled based on professional capabilities, performance, and industry influence [1]. - Yan Jianya was selected for his significant impact in the medical aesthetics field [1]. Group 2: Company Leadership - Yan Jianya, born in September 1966, holds a Bachelor's degree in Chemical Engineering from Northwest University in China [2]. - He has been the Executive Director, Chairman, and CEO of Juzi Biotechnology since November 30, 2021, and has held various leadership roles in other companies [2]. - Under his leadership, the company achieved revenue and profit growth in 2025, capitalizing on technological breakthroughs, brand upgrades, channel expansion, and policy benefits [2].

Summary of Key Points from the Conference Call Industry Overview - The conference call discusses the beauty and medical aesthetics industry, focusing on two companies: 毛戈平 (Mao Ge Ping) and 美丽田园 (Meili Tianyuan) [1][2][3]. Mao Ge Ping (毛戈平) Customer Engagement and Sales Strategy - Mao Ge Ping enhances customer loyalty through counter experiences and makeup services, with online channels attracting new customers and driving them to offline stores, achieving brand rejuvenation. Online new customer consumption accounts for over 75%, with 25%-30% converting to offline repeat purchases [1][2]. - The membership system is differentiated, with online members enjoying points and discounts, while offline members receive personalized beauty services, effectively guiding high-spending customers to offline stores and increasing overall sales. Same-store growth rate reached 18% in the first half of 2025, with a repurchase rate of 30% [1][2][6]. Product Line Expansion - Mao Ge Ping has expanded its product line to include skincare products (caviar masks, black cream) and perfumes, targeting younger consumers. The skincare category is developing steadily, with the caviar series performing exceptionally well [1][4][9]. Online and Offline Development - As of the first half of 2025, online channels surpassed offline for the first time, accounting for 25% of sales. The company aims to use online channels to attract younger customers, with the 25-30 age group increasing from 12% to 19% [5][6]. Meili Tianyuan (美丽田园) Growth Strategy - Meili Tianyuan is expanding through both organic growth and acquisitions, acquiring leading brands in the industry and adopting a "dual beauty and health" model to drive customers from lifestyle beauty to medical aesthetics, increasing average transaction value and customer lifecycle [1][3][16]. - The company has a remarkably low customer acquisition cost of about 1%, significantly lower than the industry average of 30-40%, attributed to membership asset acquisitions and cross-selling strategies [1][16][17]. Membership and Customer Retention - The company enhances membership assets through acquisitions of related businesses (e.g., yoga studios, gyms) and refined operations to improve member engagement. They have implemented over 200 standard operating procedures (SOPs) to enhance service quality and customer satisfaction [3][18]. Market Position and Future Goals - Meili Tianyuan aims to double profits in the next three years and revenues in five years, relying on both internal growth and external acquisitions to achieve these targets [20][21]. - The current landscape of the lifestyle beauty industry shows low chain penetration, with 90% of companies operating only one store, which presents opportunities for Meili Tianyuan to consolidate its market position through acquisitions [22]. Challenges and Market Dynamics - The collagen market faces challenges such as increased competition and market saturation, with many brands entering the space and consumer sensitivity to product differentiation decreasing [14]. - The profit distribution between upstream medical material suppliers and downstream medical institutions is changing, with suppliers relying more on institutions for sales, leading to a decrease in their control over pricing [15]. Conclusion - Both Mao Ge Ping and Meili Tianyuan are leveraging unique strategies to enhance customer engagement, expand product lines, and optimize membership operations, positioning themselves for growth in the competitive beauty and medical aesthetics market.

Core Viewpoint - The company has received regulatory approval for two key Class III medical devices, enhancing its position in the recombinant collagen market and addressing diverse aesthetic needs through innovative product offerings [1][2][3]. Group 1: Product Approvals - On January 15, 2026, the company received a Class III medical device registration certificate from the National Medical Products Administration of China for the "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution" [1]. - The first approved product, "Recombinant Type I α1 Collagen Lyophilized Fiber," was the first recombinant collagen injection approved in China, designed for treating dynamic facial wrinkles [1]. Group 2: Product Innovation - The newly approved "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution" is an injectable pre-mixed solution that combines equal concentrations of recombinant collagen (4.5 mg/mL) and sodium hyaluronate (4.5 mg/mL) [2]. - This product aims to improve skin smoothness through dermal injections, targeting the popular demand for skin quality improvement and hydration [2]. Group 3: Competitive Advantage - The company has established a strong competitive edge through a comprehensive "technology-brand-channel" strategy, supported by its proprietary recombinant collagen and synthetic biology technology platform [3]. - The approval of two Class III medical devices validates the platform's compliance and advanced nature, paving the way for future product expansion [3]. - The dual-brand strategy ("Kefumei" and "Keli Jin") and established hospital channels enhance the penetration of medical aesthetic products, transitioning the brand from skincare to medical-grade [3]. Group 4: Financial Projections - The company projects EPS of 1.82, 2.12, and 2.46 yuan for the years 2025 to 2027, with corresponding latest P/E ratios of 17.2, 14.8, and 12.8 times [3].

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Insights - The company has received approval for the world's first injectable recombinant collagen and hyaluronic acid composite solution, marking a significant milestone in its product offerings [8] - The company is expected to see a compound annual growth rate (CAGR) in revenue of 49.0% in 2023, followed by 57.2% in 2024, and a more moderate growth of 15.8% and 14.7% in 2026 and 2027 respectively [6][8] - The company has a strong pipeline in the aesthetic medicine sector, with two approved recombinant collagen products, which are anticipated to drive substantial revenue growth [8] Financial Summary - Closing price is HKD 35.40, with a market capitalization of HKD 37.91 billion [6][7] - Projected revenue for 2023 is RMB 3,524.14 million, increasing to RMB 7,428.23 million by 2027 [6] - Projected net profit for 2025-2027 is RMB 19.3 billion, RMB 22.6 billion, and RMB 25.4 billion respectively, with a notable decline of 6.3% in 2025 followed by growth in subsequent years [8] - The company maintains a low debt-to-asset ratio of 18.58% [7]